| 1. |
Qiu H, Cao S, Xu R. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun (Lond), 2021, 41(10): 1037-1048.
|
| 2. |
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024, 74(3): 229-263.
|
| 3. |
Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent, 2024, 4(1): 47-53.
|
| 4. |
Potter AL, Rosenstein AL, Kiang MV, et al. Association of computed tomography screening with lung cancer stage shift and survival in the United States: quasi-experimental study. Bmj, 2022, 376: e069008.
|
| 5. |
Meyer ML, Peters S, Mok TS, et al. Lung cancer research and treatment: global perspectives and strategic calls to action. Ann Oncol, 2024, 35(12): 1088-1104.
|
| 6. |
de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med, 2020, 382(6): 503-513.
|
| 7. |
Abrahams JM, Creekmur B, Lee JS, et al. Neighborhood-Level Socioeconomic Disadvantage and Adherence to Guidelines for the Evaluation of Patients With Incidentally Detected Pulmonary Nodules. Chest, 2025, 167(5): 1497-1508.
|
| 8. |
Robbins HA, Katki HA, Cheung LC, et al. Insights for Management of Ground-Glass Opacities From the National Lung Screening Trial. J Thorac Oncol, 2019, 14(9): 1662-1665.
|
| 9. |
Heeke S, Gay CM, Estecio MR, et al. Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes. Cancer Cell, 2024, 42(2): 225-237. e5.
|
| 10. |
初霞, 赵伟, 王保健. 血浆无细胞DNA中SHOX2和PTGER4基因甲基化检测有助于肺结节患者的鉴别诊断. 细胞与分子免疫学杂志, 2019, 35(04): 357-361.
|
| 11. |
Liu MC, Oxnard GR, Klein EA, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol, 2020, 31(6): 745-759.
|
| 12. |
Seijo LM, Peled N, Ajona D, et al. Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges. J Thorac Oncol, 2019, 14(3): 343-357.
|
| 13. |
Zhao M, Xue G, He B, et al. Integrated multiomics signatures to optimize the accurate diagnosis of lung cancer. Nat Commun, 2025, 16(1): 84.
|
| 14. |
Rami-Porta R, Nishimura KK, Giroux DJ, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol, 2024, 19(7): 1007-1027.
|
| 15. |
Disease YPCMCfI, Association PCoRMoYH, Diagnosis PCoE, et al. 肺结节规范化诊治专家共识. 结核与肺部疾病杂志, 2024, 5(05): 388-397.
|
| 16. |
罗汶鑫, 李为民. 肺癌的表观遗传学研究进展及其临床意义. 中国呼吸与危重监护杂志, 2018, 17(03): 313-318.
|
| 17. |
Hu S, Tao J, Peng M, et al. Accurate detection of early-stage lung cancer using a panel of circulating cell-free DNA methylation biomarkers. Biomark Res, 2023, 11(1): 45.
|
| 18. |
He J, Wang B, Tao J, et al. Accurate classification of pulmonary nodules by a combined model of clinical, imaging, and cell-free DNA methylation biomarkers: a model development and external validation study. Lancet Digit Health, 2023, 5(10): e647-e656.
|
| 19. |
association TmcoCa-c. 肿瘤DNA甲基化标志物检测及临床应用专家共识(2024版). 中国癌症防治杂志, 2024, 16(02): 129-142.
|
| 20. |
黄玉阳, 赵春玲, 张冰璐, 等. FUT7甲基化联合CT影像特征预测肺腺癌发生风险的列线图模型. 中国呼吸与危重监护杂志, 2024, 23(02): 95-104.
|
| 21. |
Dai J, Yu G, Yu J. Can CT imaging features of ground-glass opacity predict invasiveness? A meta-analysis. Thorac Cancer, 2018, 9(4): 452-458.
|
| 22. |
Niu R, Shao X, Shao X, et al. Lung Adenocarcinoma Manifesting as Ground-Glass Opacity Nodules 3 cm or Smaller: Evaluation With Combined High-Resolution CT and PET/CT Modality. AJR Am J Roentgenol, 2019, 213(5): W236-W245.
|
| 23. |
Chen H, Ma Y, Xu J, et al. Circulating microbiome DNA as biomarkers for early diagnosis and recurrence of lung cancer. Cell Rep Med, 2024, 5(4): 101499.
|